S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

CVE:AQSAequus Pharmaceuticals Stock Price, Forecast & News

C$0.10
0.00 (-4.55 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
C$0.10
Now: C$0.11
C$0.11
50-Day Range
C$0.07
MA: C$0.08
C$0.11
52-Week Range
C$0.07
Now: C$0.11
C$0.18
Volume257,500 shs
Average Volume90,078 shs
Market CapitalizationC$11.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Topiramate and Oxcarbazepine extended-release tablets for the treatment of epilepsy. Its development stage product candidates include AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and irritability associated with autistic disorders, as well as depressive disorders; AQS1303, a transdermal pyridoxine/ doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304 to treat neurological disorders. The company has a collaboration agreement with Scientus Pharma Inc. for the development and commercial supply of specific cannabinoid extracts; and licensing agreement with Supernus Pharmaceuticals, Inc. for the development and commercialization of products for the treatment of central nervous system disorders. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-3367906

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$1.88 million
Cash FlowC$0.01 per share
Book ValueC($0.02) per share

Profitability

Miscellaneous

Employees10
Market CapC$11.73 million
Next Earnings Date8/25/2020 (Estimated)
OptionableNot Optionable
C$0.10
0.00 (-4.55 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AQS News and Ratings via Email

Sign-up to receive the latest news and ratings for AQS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aequus Pharmaceuticals (CVE:AQS) Frequently Asked Questions

How has Aequus Pharmaceuticals' stock been impacted by COVID-19?

Aequus Pharmaceuticals' stock was trading at C$0.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AQS shares have decreased by 4.5% and is now trading at C$0.11.
View which stocks have been most impacted by COVID-19
.

When is Aequus Pharmaceuticals' next earnings date?

Aequus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020.
View our earnings forecast for Aequus Pharmaceuticals
.

How were Aequus Pharmaceuticals' earnings last quarter?

Aequus Pharmaceuticals Inc (CVE:AQS) posted its quarterly earnings data on Monday, June, 1st. The company reported ($0.01) EPS for the quarter. The company had revenue of $0.58 million for the quarter.
View Aequus Pharmaceuticals' earnings history
.

Has Aequus Pharmaceuticals been receiving favorable news coverage?

News stories about AQS stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aequus Pharmaceuticals earned a coverage optimism score of -1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Aequus Pharmaceuticals
.

Who are some of Aequus Pharmaceuticals' key competitors?

What other stocks do shareholders of Aequus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aequus Pharmaceuticals investors own include Growlife (PHOT), Terra Tech (TRTC), Acorn Energy (ACFN), CROWN CASTLE IN/SH SH (CCI), Charlotte's Web (CWBHF), Supreme Cannabis (FIRE), LiCo Energy Metals (LIC), Marijuana Company Of America (MCOA), Rogers (ROG) and Aurora Cannabis (ACB).

Who are Aequus Pharmaceuticals' key executives?

Aequus Pharmaceuticals' management team includes the following people:
  • Mr. Douglas Glen Janzen, Chairman, CEO & Pres (Age 50)
  • Ms. Ann Fehr CGA, CPA, Chief Financial Officer (Age 50)
  • Ms. Anne Michelle Stevens BSc, MHA, COO, Corp. Sec. & Director (Age 38)
  • Mr. Ian Richard Ball, Chief Commercial Officer
  • Dr. Donald Alan McAfee, Chief Scientific Officer (Age 77)

What is Aequus Pharmaceuticals' stock symbol?

Aequus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "AQS."

How do I buy shares of Aequus Pharmaceuticals?

Shares of AQS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Aequus Pharmaceuticals' stock price today?

One share of AQS stock can currently be purchased for approximately C$0.11.

How big of a company is Aequus Pharmaceuticals?

Aequus Pharmaceuticals has a market capitalization of C$11.73 million and generates C$1.88 million in revenue each year. Aequus Pharmaceuticals employs 10 workers across the globe.

What is Aequus Pharmaceuticals' official website?

The official website for Aequus Pharmaceuticals is www.aequuspharma.ca.

How can I contact Aequus Pharmaceuticals?

Aequus Pharmaceuticals' mailing address is 2820-200 Granville St, VANCOUVER, BC V6C 1S4, Canada. The company can be reached via phone at +1-604-3367906.

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.